Researchers find clue to safer obesity drugs

Nov 25, 2008

(PhysOrg.com) -- Once hailed as a miracle weight-loss drug, Fen-phen was removed from the market more than a decade ago for inducing life-threatening side effects, including heart valve lesions. Scientists at UT Southwestern Medical Center are trying to understand how Fen-phen behaves in the brain in order to develop safer anti-obesity drugs with fewer side effects.

In a study appearing in the Nov. 25 issue of Neuron, the researchers define a circuit in the brain that explains the ways fenfluramine, a component of Fen-phen, suppresses appetite.

"Our findings provide evidence that the neural circuit we've proposed is sufficient for the neurotransmitter serotonin to regulate food intake and body weight, " said Dr. Joel Elmquist, professor of internal medicine and pharmacology at UT Southwestern and senior author of the study. "Fen-phen works directly on this pathway. Unfortunately, that drug also adversely affects peripheral tissue such as the heart."

For the current study, the researchers engineered mice in which the expression of a serotonin receptor called 5-hydroxytryptamine 2C was blocked throughout the entire body. This was previously known to produce obese mice resistant to the anorexic actions of fenfluramine. When activated by serotonin, however, this receptor is also known to suppress appetite. Using this mouse model, the authors engineered another set of mice in which the same serotonin receptor was blocked everywhere in the body except within a group of brain cells called pro-opiomelanocortin, or POMC, neurons. The POMC neurons, which are found in the hypothalamus, are also known to play an important role in suppressing appetite and inducing weight loss.

The researchers found that the animals with no serotonin 2c receptors expectedly developed obesity as well as other metabolism disorders such as increased food intake, hyperactivity and leptin insensitivity. They also were prone to spontaneous seizures, said Dr. Elmquist.

In contrast, the mice in which the serotonin receptor was re-expressed and functioning only in the POMC neurons stayed slim and responded to fenfluramine.

"The POMC-specific reactivation of the receptor only in POMC neurons normalizes the abnormal metabolism in these mice," Dr. Elmquist said. "The animals don't eat excessively. Their hyperactivity is also gone."

Previous work from the UT Southwestern group led to the hypothesis that Fen-phen worked by activating the serotonin 2c receptor in the POMC neurons in the hypothalamus. The current work provides genetic proof supporting this model.

"Conventional wisdom is that fenfluramine increases serotonin release that then activates serotonin receptors in the brain to regulate food intake and body weight, but unfortunately, this drug also causes lesions in heart valves," he said. "If you could develop a drug that would travel to both the brain and the peripheral tissues, and then give a blocker to protect the heart, it's possible that you could prevent the harmful side effects and still aid weight loss. Admittedly, that's a bit farfetched, but this mouse model could be used to test that theory."

The team's next step is to determine whether they've identified the sole circuit required to suppress appetite and induce weight loss.

Provided by UT Southwestern Medical Center

Explore further: The impact of bacteria in our guts

add to favorites email to friend print save as pdf

Related Stories

Scientists find measles' natural nemesis

Jan 20, 2011

Scientists at The Scripps Research Institute have found that a known enzyme in cells protects against measles virus, likely by altering the virus's genetic material, RNA. Cells lacking the enzyme become highly vulnerable ...

Recommended for you

The impact of bacteria in our guts

Aug 22, 2014

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

Aug 22, 2014

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

Aug 22, 2014

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0